Intravenous showed no clear difference in severe PPH ≥ 1000 mL compared with intramuscular oxytocin (moderate certainty).
Intravenous showed no clear difference in serious maternal morbidity compared with intramuscular oxytocin (moderate certainty).
Intravenous leads to lower PPH ≥ 500 mL compared with intramuscular oxytocin (high certainty).
Intravenous showed no clear difference in use of additional uterotonics compared with intramuscular oxytocin (low certainty).
Intravenous leads to lower blood transfusion compared with intramuscular oxytocin (high certainty).
Intravenous showed no clear difference in hypotension compared with intramuscular oxytocin (moderate certainty).
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
Intravenous may leads to lower relapse at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower continuing frequently‐relapsing or steroid‐dependent SSNS at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in relapse at end of study compared with oral cyclophosphamide (low certainty).
The review found no eligible studies for this question.
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
Intravenous may leads to higher insertion failures compared with intraosseous route (low certainty).